CELIA
OREJA GUEVARA
Profesora asociada de Ciencias de la Salud
Mayo Clinic
Rochester, Estados UnidosMayo Clinic-ko ikertzaileekin lankidetzan egindako argitalpenak (7)
2024
2023
-
Ravulizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder
Annals of Neurology, Vol. 93, Núm. 6, pp. 1053-1068
2022
-
Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension
Multiple Sclerosis Journal, Vol. 28, Núm. 3, pp. 480-486
-
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021
Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 28, Núm. 9, pp. 1424-1456
2021
-
Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial
Multiple Sclerosis and Related Disorders, Vol. 47
-
Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD
Annals of Neurology, Vol. 89, Núm. 6, pp. 1088-1098
2020
-
Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis
Frontiers in Pediatrics, Vol. 8